title: Pancreatitis induced by pentavalent antimonial agents during treatment of leishmaniasis.
abstract: Pentavalent antimony (Sbv), formulated as sodium stibogluconate or meglumine antimoniate, is the standard treatment for the leishmaniases. In 16 of 17 consecutive, prospectively observed patients in Washington D.C., serum levels of amylase and lipase rose to abnormal values after therapy with sodium stibogluconate was started; 12 of 17 had symptoms of pancreatitis. Sbv therapy was continued to completion in 7 of 17 patients and interrupted in 10 of 17. Pancreatitis improved in every patient after Sbv therapy was stopped. Sbv treatment was resumed after brief interruptions in 6 of 10 patients. All six of these patients had flares of pancreatitis, but each completed therapy. Subsequently, we measured amylase and lipase levels in stored sera from 32 patients treated in Peru with either sodium stibogluconate or meglumine antimoniate for mucosal leishmaniasis. In all 32 Peruvian patients, serum amylase and lipase rose to abnormal levels during Sbv therapy; 11 of 32 had symptoms of pancreatitis. Standard Sbv regimens induce pancreatitis in almost all patients, but continued therapy is often tolerated; pancreatitis subsides when therapy is stopped, and rechallenge may be tolerated after a brief halt in treatment.
authors.affiliation: Infectious Disease Service, Walter Reed Army Medical Center, Washington, D.C. 20307-5100.
authors.forename: R A
authors.initials: RA
authors.lastname: Gasser
authors.forename: A J
authors.initials: AJ
authors.lastname: Magill
authors.forename: C N
authors.initials: CN
authors.lastname: Oster
authors.forename: E D
authors.initials: ED
authors.lastname: Franke
authors.forename: M
authors.initials: M
authors.lastname: Grögl
authors.forename: J D
authors.initials: JD
authors.lastname: Berman
mesh_terms: D000328:Adult; D000681:Amylases / Q000097:blood; D000967:Antimony Sodium Gluconate / Q000008:administration & dosage / Q000009:adverse effects*; D000981:Antiprotozoal Agents / Q000008:administration & dosage / Q000009:adverse effects; D004219:District of Columbia; D006801:Humans; D007897:Leishmaniasis, Mucocutaneous / Q000188:drug therapy; D007898:Leishmaniasis, Visceral / Q000188:drug therapy; D008049:Lipase / Q000097:blood; D008297:Male; D008536:Meglumine / Q000008:administration & dosage / Q000009:adverse effects; D000077485:Meglumine Antimoniate; D008875:Middle Aged; D009942:Organometallic Compounds / Q000008:administration & dosage / Q000009:adverse effects; D010195:Pancreatitis / Q000139:chemically induced* / Q000201:enzymology; D010568:Peru; D011446:Prospective Studies
chemical_list: D000981:Antiprotozoal Agents; D009942:Organometallic Compounds; D008536:Meglumine; D000077485:Meglumine Antimoniate; D008049:Lipase; D000681:Amylases; D000967:Antimony Sodium Gluconate